TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00361907

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Effect of Pulsatile IV insulin on diabetic pt blood markers
Description: Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
Study: NCT06494566

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Omega-3 capsule
Study: NCT02114359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/cisplatin
Description: Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
Study: NCT06494566

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mineral Oil
Description: Mineral Oil Capsule
Study: NCT03942575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Wound dressing with negative pressure on closed incisions
Study: NCT00838994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Study: NCT01057082

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven
Description: Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
Study: NCT02114359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1/cisplatin
Description: S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/oxaliplatin
Description: Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/oxaliplatin
Description: 5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 1000mg/m2 po bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr \<60ml/min, 30mg/m2 po bid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
Study: NCT00440232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frovatriptan
Description: Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert tab identical in appearance to Frovatriptan
Study: NCT02924766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will start with niraparib 200 mg once daily.
Study: NCT05058105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 Placebo （ IV 120min）
Description: D1 qd;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 1000 mg （ IV 120min）
Description: D4 qd;
Study: NCT01057082

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Juven
Description: Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
Study: NCT01190852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine, Fluticasone
Description: TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
Study: NCT05058105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Placebo （ IV 120min）
Description: D4 qd;
Study: NCT01190852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine mono
Description: REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine
Description: COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
Study: NCT02245529

Intervention type: DRUG
Intervention: Tamsulosin
Study: NCT00349206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study: NCT01034462

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
Study: NCT00349206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study: NCT02425150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal reshaping/crosslinking (CRXL)
Description: The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Crosslinking (CXL)
Description: The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
Study: NCT05058105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 1000mg and Meropenem 1000mg （ IV 120min）
Description: D7 qd;~D8\~ D14 q8h;~D15 qd;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 Placebo and Meropenem 1000mg （ IV 120min）
Description: D7 qd;~D8\~ D14 q8h;~D15 qd;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 1000mg and Meropenem 2000mg （ IV 120min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Study: NCT00911495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1070
Description: Intravenous GMI-1070 given as two doses over the course of one day
Study: NCT04332354

Intervention type: OTHER
Intervention: routine care. No intervention
Description: no intervention
Study: NCT00708162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elvitegravir
Description: Elvitegravir (EVG) tablet administered orally once daily with food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir tablet administered orally twice daily according to prescribing information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVG placebo
Description: Placebo to match elvitegravir administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAL placebo
Description: RAL placebo administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background regimen
Description: Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background regimen
Description: Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
Study: NCT03367481

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush type
Description: In this cross-over study, the participants will use either a soft brush (control) and the medium brush (test).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush type
Description: In this cross-over study, the participants will use either a soft brush (control) and the medium brush (test).
Study: NCT02175888

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days
Study: NCT03582202

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional assessment and therapy
Description: Nutritional screening, nutritional plan, follow-up and instructions on discharge

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Nutritional handling by nurse
Study: NCT04474067

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, with no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, with no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, with no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, with no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, with no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, with no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, with no intervention.
Study: NCT00065507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir (ADV)
Description: Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
Study: NCT03635957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: pegloticase administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: oral MTX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Gout Flare Prophylaxis
Description: It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al.2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion Reaction (IR) Prophylaxis
Description: For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.
Study: NCT03960957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Description: Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
Study: NCT03635957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
Study: NCT03960957

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment of glabellar facial lines with placebo
Study: NCT00829400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo Brain Age
Description: Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
Study: NCT05058105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 Placebo and Meropenem 2000m（ IV 120min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 1000mg and Meropenem 2000mg （ IV 180min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 Placebo and Meropenem 2000m（ IV 180min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 2000mg and Meropenem 2000mg（ IV 180min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 Placebo and Meropenem 2000mg（ IV 180min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Study: NCT03630198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid with lidocaine
Description: Intralesional corticosteroid injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid with normal saline
Description: Intralesional corticosteroid injection
Study: NCT01563120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin up to 2550mg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glybenclamide
Description: glybenclamide up to 20mg per day.
Study: NCT03938220

Intervention type: DEVICE
Intervention: Electrical Cardiometry
Description: Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.

Intervention type: DEVICE
Intervention: Electrical Cardiometry
Description: Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
Study: NCT04270162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training 1
Description: For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training 2
Description: Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training 3
Description: The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
Study: NCT03332719

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Study: NCT03566615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water
Description: using water instead of traditional air insufflation to help insertion
Study: NCT03332719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT02537262

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate beverage
Description: Carbohydrate group drinks carbohydrate beverage 400ml(9PM\~MN) the day before the surgery and 200ml three hours before the surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NPO(None Per Oral)
Description: NPO group does not drink any water from the MN before the surgery.
Study: NCT01691014

Intervention type: OTHER
Intervention: non-interventional study
Description: Study with 4 arms/groups with 36 patients per group. In total 144 patients.

Intervention type: OTHER
Intervention: non-interventional study
Description: Study with 4 arms/groups with 36 patients per group. In total 144 patients.

Intervention type: OTHER
Intervention: non-interventional study
Description: Study with 4 arms/groups with 36 patients per group. In total 144 patients.

Intervention type: OTHER
Intervention: non-interventional study
Description: Study with 4 arms/groups with 36 patients per group. In total 144 patients.
Study: NCT01129037

Intervention type: OTHER
Group type: OTHER
Intervention: Goal directed fluid management based on continuous monitoring of stroke volume
Description: Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased \< 10% in response to receding VL: SV is optimized, no further VL required.
Study: NCT03598205

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DIABEC plus intravitreal dexamethazone
Description: Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)
Study: NCT02387801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study: NCT04072367

Intervention type: DEVICE
Group type: OTHER
Intervention: NeVa Stent Retrievers
Description: thrombus removal

Intervention type: DEVICE
Group type: OTHER
Intervention: Solitaire Stent Retrievers
Description: thrombus removal
Study: NCT01219036

Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide (directly observed)
Description: Budesonide 1600 micrograms daily directly observed for 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide (directly observed)
Description: Budesonide 1600 micrograms daily directly observed for 7 days
Study: NCT03281330

Intervention type: BEHAVIORAL
Intervention: auditory cues and music during walking
Description: the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
Study: NCT01305850

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren plus Losartan
Description: Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril plus Losartan
Description: Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg